Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease

被引：29

作者：

Bannai, Ei ^{[1
]}

Yamashita, Hiroyuki ^{[1
]}

Kaneko, Shunta ^{[1
]}

Ueda, Yo ^{[1
]}

Ozaki, Takashi ^{[1
]}

Tsuchiya, Haruka ^{[1
]}

Takahashi, Yuko ^{[1
]}

Kaneko, Hiroshi ^{[1
]}

Kano, Toshikazu ^{[1
]}

Mimori, Akio ^{[1
]}

机构：

[1] Natl Ctr Global Hlth & Med, Div Rheumat Dis, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan

来源：

MODERN RHEUMATOLOGY | 2016年 / 26卷 / 02期

关键词：

Adult-onset Still's disease; Tocilizumab; Macrophage activation syndrome; MACROPHAGE ACTIVATION SYNDROME; TUMOR-NECROSIS-FACTOR; RHEUMATOID-ARTHRITIS; RECEPTOR ANTIBODY; IL-6; RECEPTOR; EFFICACY; INTERLEUKIN-6; AGENTS; TRIAL;

D O I：

10.3109/14397595.2014.899178

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To evaluate the effects of tocilizumab (TCZ) on adult-onset Still's disease (AOSD), we reviewed medical records of seven patients with refractory AOSD treated with TCZ at our institution. TCZ therapy might allow rapid corticosteroid tapering and help maintain remission status, that is, resolution of clinical symptoms and normalization of biomarkers such as CRP and ferritin. Patients, however, should be monitored for the development of macrophage activation syndrome when TCZ is administered for active AOSD.

引用

页码：297 / 301

页数：5

共 50 条

[1] Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD)
Yoshimura, M.
Makiyama, J.
Koga, T.
Miyashita, T.
Izumi, Y.
Torigoshi, T.
Motokawa, S.
Eguchi, K.
Migita, K.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (01) : 141 - 142
[2] EFFECTIVE TREATMENT OF TOCILIZUMAB IN PATIENTS WITH REFRACTORY ADULT-ONSET STILL'S DISEASE
Cheng, T.
Chen, Z.
Tan, J.
Jiang, Y.
Liao, Z.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1862 - 1862
[3] Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment
Lee, Young Ho
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (12)
[4] TOCILIZUMAB IN REFRACTORY ADULT-ONSET STILL'S DISEASE: MULTICENTER STUDY OF 27 PATIENTS
Ortiz-Sanjuan, F.
Blanco, R.
Narvaez, F.
Rubio-Romero, E.
Castaneda, S.
Hernandez, M.
Sifuentes-Giraldo, W.
Ros Vilamajo, I.
Mas, A.
Gallego Flores, A.
Manrique-Arija, S.
Gomez Arango, C.
Rosello, R.
Marras, C.
Plasencia-Rodriguez, C.
Llobet, J.
Velloso-Feijoo, M.
Freire, M.
Caracuel, M.
Moll Tuduri, M.
Lluch, P.
Loricera, J.
Calvo-Rio, V.
Gonzalez-Gay, M.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 323 - 324
[5] A Pilot Study on Tocilizumab for Treating Refractory Adult-Onset Still’s Disease
Ting Li
Liyang Gu
Xiaodong Wang
Li Guo
Hui Shi
Chengde Yang
Sheng Chen
Scientific Reports, 7
[6] A Pilot Study on Tocilizumab for Treating Refractory Adult-Onset Still's Disease
Li, Ting
Gu, Liyang
Wang, Xiaodong
Guo, Li
Shi, Hui
Yang, Chengde
Chen, Sheng
SCIENTIFIC REPORTS, 2017, 7
[7] Response to: 'Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment' by Lee
Kaneko, Yuko
Kameda, Hideto
Ikeda, Kei
Ishii, Tomonori
Murakami, Kosaku
Takamatsu, Hyota
Tanaka, Yoshiya
Abe, Takayuki
Takeuchi, Tsutomu
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (12)
[8] Successful treatment with tacrolimus of refractory adult-onset Still's disease
Ohe, Masashi
Oku, Kenji
Kono, Michihito
Bohgaki, Toshiyuki
KOREAN JOURNAL OF INTERNAL MEDICINE, 2014, 29 (02): : 259 - 261
[9] Tocilizumab for the treatment of adult-onset Still's disease
Castaneda, Santos
Martinez-Quintanilla, Dolores
Martin-Varillas, Jose L.
Garcia-Castaneda, Noelia
Atienza-Mateo, Belen
Gonzalez-Gay, Miguel A.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (04) : 273 - 286
[10] Tocilizumab for multirefractory adult-onset Still's disease
De Bandt, M.
Saint-Marcoux, B.
ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (01) : 153 - 154

← 1 2 3 4 5 →